
Product Data Sheet

Product Name: CFM 1571 hydrochloride

Cat. No.: GC17431

Chemical Properties

Cas. No. 1215548-30-3

Chemical Name 1-benzyl-3-(3-(dimethylamino)propoxy)-N-(4-methoxyphenyl)-1H-pyrazole-5-carboxamide hydrochloride

SMILES CN(CCCOC(C=C1C(NC2=CC=C(OC)C=C2)=O)=NN1CC3=CC=CC=C3)C.Cl

Formula $C_{23}H_{28}N_4O_3.HCl$ M.Wt 444.95

Solubility DMSO : 100 mg/mL (224.74 mM; Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

IC50: 2.84 μM for platelet

Soluble guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric oxide (NO). Impaired bioavailability and/or responsiveness to endogenous NO has been implicated in the pathogenesis of cardiovascular and other diseases. CFM 1571 is an activator of the nitric oxide receptor, soluble guanylate cyclase.

In vitro: CFM 1571 demonstrated potent activation of soluble guanylate cyclase and potent inhibition of platelet aggregation. CFM 1571 also showed enzyme activity similar to benzydamine. CFM 1571 was additionally assayed against the NOS isoforms, and minimal inhibition was observed with iNOS (25%) and nNOS (17%). Furthermore CFM 1571 shows no significant activity at any of the other enzymes studied [1].

In vivo: Pharmacokinetic studies in rats showed that compound CFM 1571 exhibits modest oral bioavailability (12%). Furthermore 32 has an excellent selectivity profile

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

notably showing no significant inhibition of phosphodiesterases or nitric oxide synthases [1].

Clinical trial: Up to now, CFM 1571 is still in the preclinical development stage.

Reference:

[1] Selwood DL, Brummell DG, Budworth J, Burtin GE, Campbell RO, Chana SS, Charles IG, Fernandez PA, Glen RC, Goggin MC, Hobbs AJ, Kling MR, Liu Q, Madge DJ, Meillerais S, Powell KL, Reynolds K, Spacey GD, Stables JN, Tatlock MA, Wheeler KA, Wishart G, Woo CK. Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase. *J Med Chem.* 2001 Jan 4;44(1):78-93.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA